1. |
Marshall SM. Recent advances in diabetic nephropathy. Postgrad Med J, 2004; 80(949): 624-633.
|
2. |
Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care, 2005; 28(1): 164-176.
|
3. |
American Diabetes Association (ADA). Standards of medical care in diabetes. Diabetes Care, 2006; 29(Suppl 1): 4-42.
|
4. |
Dinneen SF, Griffin S. An intensive intervention reduced cardiovascular and microvascular events in type 2 diabetes and microalbuminuria. ACP Journal Club,2003; 139(2):29.
|
5. |
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet, 1998; 352(9131): 837-853.
|
6. |
Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-Term Results of the Kumamoto Study on Optimal Diabetes Control in Type 2 Diabetic Patients. Diabetes Care, 2000; 23(Suppl 2): B21-29.
|
7. |
Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes, 2005; 54(7): 2206-2211.
|
8. |
Strippoli GFM, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. In: The Cochrane Library, 2006,Issue 2.
|
9. |
Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. In: The Cochrane Library,2005, Issue 3.
|
10. |
Ruggenenti P, Fassi A, Ilieva AP, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med, 2004; 351(19): 1941-1951.
|
11. |
Rabbat CG. Losartan was renoprotective in diabetic nephropathy independent of its effect on blood pressure. ACP Journal Club,2002; 136(3): 82-84.
|
12. |
Irbesartan reduced progression of nephropathy caused by type 2 diabetes independent of the effect on blood pressure. ACP Journal Club,2002; 136(3):82-84.
|
13. |
Schjoedt KJ, Jacobsen P, Rossing K, et al. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone. Hormone and Metablic Research, 2005; 37(Suppl 1): 4-8.
|
14. |
UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998; 317(7 160): 703-713.
|
15. |
Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis, 2005; 45(3): 485-493.
|
16. |
Gross JL, Zelmanovitz T, Moulin CC, et al. Effect of a chicken-based diet on renal function and lipid profile in patient with type 2 diabetes: a randomized crossover trial. Diabetes Care, 2002; 25(4): 645-651.
|
17. |
Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab, 2000; 26(Suppl 4): 54-63.
|